Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 13/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299967 | 0.98 | NFE2L2 (0.64) | NFE2L2HPGDPTGESMAOBALDH1A1 | |
| SCHEMBL3079542 | 0.95 | HPGD (0.56) | NFE2L2HPGDPTGESMAOBALDH1A1 | |
| SCHEMBL3072288 | 0.94 | NFE2L2 (0.59) | NFE2L2HPGDPTGESMAOBALDH1A1 | |
| SCHEMBL16761852 | 0.93 | HPGD (0.52) | NFE2L2HPGDPTGESMAOBALDH1A1 | |
| SCHEMBL1299878 | 0.90 | HPGD (0.62) | NFE2L2HPGDPTGESALDH1A1LMNA | |
| SCHEMBL1299546 | 0.89 | HPGD (0.63) | NFE2L2HPGDPTGESALDH1A1LMNA | |
| SCHEMBL18789967 | 0.86 | ALDH1A1 (0.48) | NFE2L2HPGDPTGESMAOBALDH1A1 | |
| SCHEMBL30973653 | 0.86 | HPGD (0.50) | NFE2L2HPGDALDH1A1LMNAMAPT | |
| SCHEMBL1299143 | 0.83 | HPGD (0.58) | HPGDALDH1A1GRM2 | |
| SCHEMBL3085585 | 0.82 | HPGD (0.46) | NFE2L2HPGDPTGESALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-8637558-B2 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2014-01-28 | — | — | US | disclosed |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2011-11-03 | — | — | US | disclosed |
| EP-2383263-A2 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | Industry-academic Cooperation Foundation, Chosun University (KR) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | HPGD, CYP27B1, GCDH | NFE2L2 284/4885HPGD 1/4885PTGES 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.